Medicxi Ventures Management Ltd
CIK: 1715579
New Positions
0
Increased
0
Exit Positions
0
Holdings (3)
Q3 2026 13F, quarter ended Sep 30, 2026, filed Nov 2, 2026
- PHAT
PHATHOM PHARMACEUTICALS INC
$54.49M
7.46M sh43.02%+0.0% - NAMS
NEWAMSTERDAM PHARMA COMPANY
$53.07M
2.18M sh41.90%-1.2% - AURA
AURA BIOSCIENCES INC
$19.09M
3.04M sh15.07%+0.0%
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 PHAT PHATHOM PHARMACEUTICALS INC | 7.46M | $54.49M | +0.0% | 43.02% | Q3 2026 |
 NAMS NEWAMSTERDAM PHARMA COMPANY | 2.18M | $53.07M | -1.2% | 41.90% | Q3 2026 |
 AURA AURA BIOSCIENCES INC | 3.04M | $19.09M | +0.0% | 15.07% | Q3 2026 |
1-3 of 3 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About Medicxi Ventures Management Ltd
Medicxi Ventures Management Ltd is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1715579). Signal8 holds 22 13F filings from it.
Its most recent 13F holdings report covers Q3 2026 (the quarter ended Sep 30, 2026) and was filed on Nov 2, 2026. That report lists 3 securities, not counting options, the same number as in Q2 2026.
Its three largest reported positions, in order, are PHATHOM PHARMACEUTICALS INC (PHAT), NEWAMSTERDAM PHARMA COMPANY (NAMS) and AURA BIOSCIENCES INC (AURA).
Recent 13F filings by Medicxi Ventures Management Ltd
- Q3 2026: 13F-HR filed Nov 2, 2026, listing 3 securities.
- Q2 2026: 13F-HR filed Aug 4, 2026, listing 3 securities.
- Q1 2026: 13F-HR filed Apr 20, 2026, listing 4 securities.
- Q4 2025: 13F-HR filed Jan 23, 2026, listing 5 securities.
- Q3 2025: 13F-HR filed Oct 17, 2025, listing 5 securities.
- Q2 2025: 13F-HR filed Jul 8, 2025, listing 5 securities.